As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
9 Analysts have issued a Citius Pharmaceuticals Inc forecast:
9 Analysts have issued a Citius Pharmaceuticals Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -41 -41 |
5%
5%
|
|
| EBIT (Operating Income) EBIT | -41 -41 |
5%
5%
|
|
| Net Profit | -41 -41 |
4%
4%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
| Head office | United States |
| CEO | Leonard Mazur |
| Employees | 23 |
| Founded | 2007 |
| Website | www.citiuspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


